TRxADE HEALTH, Inc. (MEDS) Income Statement Analysis

See more : GE T&D India Limited (GET&D.NS) Income Statement Analysis – Financial Results

Complete financial analysis of TRxADE HEALTH, Inc. (MEDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TRxADE HEALTH, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.

You may be interested

TRxADE HEALTH, Inc. (MEDS)

Industry: Medical - Pharmaceuticals

Sector: Healthcare

Website: https://www.trxadehealth.com

About TRxADE HEALTH, Inc.

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2008	2007	2006
Revenue	8.27M	11.45M	9.89M	17.12M	7.44M	3.83M	2.93M	2.48M	4.99M	1.50M	955.88K	806.05K	0.00	0.00	0.00
Cost of Revenue	5.67M	6.00M	5.14M	11.42M	2.57M	449.05K	0.00	16.36K	1.93M	440.05K	944.07K	689.81K	0.00	0.00	0.00
Gross Profit	2.60M	5.45M	4.75M	5.71M	4.87M	3.38M	2.93M	2.47M	3.06M	1.06M	11.81K	116.24K	0.00	0.00	0.00
Gross Profit Ratio	31.41%	47.62%	47.99%	33.33%	65.50%	88.28%	100.00%	99.34%	61.38%	70.59%	1.24%	14.42%	0.00%	0.00%	0.00%
Research & Development	1.38M	1.16M	1.37M	662.73K	647.14K	949.95K	375.17K	286.76K	319.44K	319.44K	611.71K	198.41K	0.00	0.00	3.57K
General & Administrative	8.48M	7.05M	8.81M	7.49M	4.38M	2.35M	2.27M	3.30M	3.70M	2.11M	2.10M	266.95K	28.50M	0.00	5.16K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	147.63K	355.12K	374.62K	0.00	0.00	0.00	0.00	0.00
SG&A	8.48M	7.05M	8.81M	7.49M	4.38M	2.35M	2.27M	3.45M	4.05M	2.49M	2.10M	266.95K	28.50M	24.77K	5.16K
Other Expenses	14.54K	1.60M	-1.23M	3.25M	72.08K	161.64K	67.50K	131.27K	0.00	0.00	0.00	0.00	0.00	3.42K	0.00
Operating Expenses	9.86M	8.21M	8.81M	7.49M	4.38M	3.30M	2.27M	3.45M	4.05M	2.49M	2.10M	266.95K	28.50M	28.19K	8.73K
Cost & Expenses	15.54M	14.20M	13.96M	18.90M	6.94M	3.75M	2.27M	3.47M	5.98M	2.93M	3.04M	956.76K	28.50M	28.19K	8.73K
Interest Income	4.20K	20.99K	23.59K	29.39K	53.23K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	1.20M	336.21K	23.59K	29.39K	53.23K	57.54K	157.06K	151.50K	130.14K	4.15K	7.28K	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.05M	194.70K	138.91K	102.52K	94.73K	87.62K	-395.10K	8.67K	3.80K	4.80K	3.99K	2.63K	0.00	0.00	0.00
EBITDA	-13.72M	-1.85M	-5.15M	-2.51M	660.55K	96.65K	288.98K	-984.03K	-133.27K	-2.00M	-2.08M	-148.09K	-28.50M	-28.19K	-8.73K
EBITDA Ratio	-74.89%	-22.18%	-52.11%	-9.80%	8.88%	6.36%	24.92%	-39.65%	-19.70%	-95.35%	-217.60%	-18.37%	0.00%	0.00%	0.00%
Operating Income	-7.26M	-2.76M	-5.29M	-1.78M	565.82K	-87.62K	395.10K	-984.03K	-987.05K	-1.43M	-2.08M	-150.71K	-28.50M	-28.19K	-8.73K
Operating Income Ratio	-87.80%	-24.08%	-53.51%	-10.40%	7.61%	-2.29%	13.48%	-39.65%	-19.77%	-95.67%	-218.02%	-18.70%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-6.46M	-362.72K	-23.59K	-29.39K	-778.17K	96.65K	-106.11K	-165.83K	-119.51K	-580.57K	-7.28K	0.00	28.47M	0.00	0.00
Income Before Tax	-13.72M	-3.91M	-5.32M	-2.54M	-284.43K	9.04K	288.98K	-1.17M	-1.12M	-2.01M	-2.09M	-150.71K	-28.50K	0.00	0.00
Income Before Tax Ratio	-165.86%	-34.15%	-53.75%	-14.81%	-3.82%	0.24%	9.86%	-47.27%	-22.38%	-134.47%	-218.78%	-18.70%	0.00%	0.00%	0.00%
Income Tax Expense	5.34M	400.34K	-1.20M	29.39K	125.30K	-154.20K	-50.94K	1.62M	130.14K	576.42K	7.28K	0.00	28.50M	28.19K	8.73K
Net Income	-17.84M	-4.31M	-4.11M	-2.57M	-409.73K	9.04K	288.98K	-2.76M	-1.12M	-2.01M	-2.09M	-150.71K	-28.50M	-28.19K	-8.73K
Net Income Ratio	-215.70%	-37.65%	-41.59%	-14.98%	-5.51%	0.24%	9.86%	-111.21%	-22.38%	-134.47%	-218.78%	-18.70%	0.00%	0.00%	0.00%
EPS	-23.35	-7.63	-7.58	-4.99	-1.04	0.02	0.81	-7.89	-3.20	-6.30	-13.50	-0.97	-273.59	-0.27	-0.11
EPS Diluted	-7.49	-7.63	-7.58	-4.99	-1.04	0.02	0.81	-7.87	-3.20	-6.07	-13.35	-0.97	-269.45	-0.27	-0.11
Weighted Avg Shares Out	764.06K	564.86K	542.45K	513.71K	395.27K	388.43K	355.06K	349.64K	349.64K	319.37K	154.91K	154.91K	104.16K	105.76K	81.20K
Weighted Avg Shares Out (Dil)	2.38M	564.86K	542.45K	513.71K	395.27K	388.43K	378.74K	350.50K	349.64K	331.46K	156.69K	154.91K	105.76K	105.76K	81.20K

TRxADE HEALTH, INC. to Report Second Quarter 2022 Financial Results on Monday, July 25th at 5:00 p.m.

July 11, 2022accesswire.com

TAMPA, FL / ACCESSWIRE / July 11, 2022 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S.,...

TRxADE HEALTH, Inc. (MEDS) CEO Suren Ajjarapu on Q1 2022 Results - Earnings Call Transcript

May 9, 2022seekingalpha.com

TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Suren Ajjarapu – Founder, Chairman and Chief Executive Officer Janet Huffman – Chief Financial Officer Conference Call Participants Howard Halpern – Taglich...

TRxADE (MEDS) Reports Q1 Loss, Tops Revenue Estimates

May 9, 2022zacks.com

TRxADE (MEDS) delivered earnings and revenue surprises of -33.33% and 37.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: TRxADE (MEDS) Q1 Earnings Expected to Decline

May 2, 2022zacks.com

TRxADE (MEDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TRxADE HEALTH, INC. to Report First Quarter 2022 Financial Results on Monday, May 9th at 5:00 p.m.

April 25, 2022accesswire.com

TAMPA, FL / ACCESSWIRE / April 25, 2022 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S.,...

TRxADE HEALTH, Inc. (MEDS) CEO Suren Ajjarapu on Q4 2021 Results - Earnings Call Transcript

March 28, 2022seekingalpha.com

TRxADE HEALTH, Inc. (MEDS) CEO Suren Ajjarapu on Q4 2021 Results - Earnings Call Transcript

TRxADE HEALTH, INC. to Report Fourth Quarter and Year End 2021 Financial Results on Monday, March 28th at 5:00 p.m.

March 14, 2022accesswire.com

TAMPA, FL / ACCESSWIRE / March 14, 2022 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will...

TRxADE HEALTH to Present at Aegis Virtual Conference

February 9, 2022accesswire.com

TAMPA, FL / ACCESSWIRE / February 9, 2022 / TRxADE HEALTH, INC . (NASDAQ:MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in...

TRxADE HEALTH to Present at LD Micro Movers Virtual Event on December 1, 2021

November 17, 2021accesswire.com

TAMPA, FL / ACCESSWIRE / November 17, 2021 / TRxADE HEALTH, INC . (NASDAQ:MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today...